Protein engineering: the potential of remote mutations.

directed evolution evolutionary biology protein design protein engineering remote mutation

Journal

Biochemical Society transactions
ISSN: 1470-8752
Titre abrégé: Biochem Soc Trans
Pays: England
ID NLM: 7506897

Informations de publication

Date de publication:
30 04 2019
Historique:
received: 18 01 2019
revised: 18 01 2019
accepted: 18 02 2019
pubmed: 25 3 2019
medline: 9 11 2019
entrez: 24 3 2019
Statut: ppublish

Résumé

Engineered proteins, especially enzymes, are now commonly used in many industries owing to their catalytic power, specific binding of ligands, and properties as materials and food additives. As the number of potential uses for engineered proteins has increased, the interest in engineering or designing proteins to have greater stability, activity and specificity has increased in turn. With any rational engineering or design pursuit, the success of these endeavours relies on our fundamental understanding of the systems themselves; in the case of proteins, their structure-dynamics-function relationships. Proteins are most commonly rationally engineered by targeting the residues that we understand to be functionally important, such as enzyme active sites or ligand-binding sites. This means that the majority of the protein, i.e. regions remote from the active- or ligand-binding site, is often ignored. However, there is a growing body of literature that reports on, and rationalises, the successful engineering of proteins at remote sites. This minireview will discuss the current state of the art in protein engineering, with a particular focus on engineering regions that are remote from active- or ligand-binding sites. As the use of protein technologies expands, exploiting the potential improvements made possible through modifying remote regions will become vital if we are to realise the full potential of protein engineering and design.

Identifiants

pubmed: 30902926
pii: BST20180614
doi: 10.1042/BST20180614
doi:

Substances chimiques

Proteins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

701-711

Informations de copyright

© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Matthew Wilding (M)

Research School of Chemistry, Australian National University, Canberra, Australian Capital Territory, Australia matthew.wilding@anu.edu.au colin.jackson@anu.edu.au.
CSIRO Synthetic Biology Future Science Platform, Canberra, Australia.

Nansook Hong (N)

Research School of Chemistry, Australian National University, Canberra, Australian Capital Territory, Australia.

Matthew Spence (M)

Research School of Chemistry, Australian National University, Canberra, Australian Capital Territory, Australia.

Ashley M Buckle (AM)

Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.

Colin J Jackson (CJ)

Research School of Chemistry, Australian National University, Canberra, Australian Capital Territory, Australia matthew.wilding@anu.edu.au colin.jackson@anu.edu.au.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis
Databases, Protein Protein Domains Protein Folding Proteins Deep Learning

Prevalence and implications of fragile X premutation screening in Thailand.

Areerat Hnoonual, Sunita Kaewfai, Chanin Limwongse et al.
1.00
Humans Fragile X Mental Retardation Protein Thailand Male Female

Classifications MeSH